Hyperfine (HYPR) Projected to Announce Quarterly Earnings on Thursday

Hyperfine (NASDAQ:HYPR) will likely be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.09) per share and revenue of $4.1350 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Hyperfine (NASDAQ:HYPR) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). The firm had revenue of $3.90 million for the quarter, compared to analyst estimates of $3.54 million. Hyperfine had a negative return on equity of 98.83% and a negative net margin of 226.88%.

Hyperfine Price Performance

NASDAQ HYPR traded up $0.01 during midday trading on Tuesday, hitting $0.99. The company had a trading volume of 226,762 shares, compared to its average volume of 726,444. The firm has a 50-day moving average price of $1.28 and a 200-day moving average price of $1.26. The company has a market capitalization of $98.67 million, a PE ratio of -2.43 and a beta of 1.43. The company has a current ratio of 5.52, a quick ratio of 4.90 and a debt-to-equity ratio of 0.38. Hyperfine has a twelve month low of $0.85 and a twelve month high of $2.22.

Hedge Funds Weigh In On Hyperfine

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp raised its holdings in Hyperfine by 6.1% during the 4th quarter. State Street Corp now owns 265,195 shares of the company’s stock worth $260,000 after purchasing an additional 15,200 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Hyperfine by 47.9% in the 4th quarter. XTX Topco Ltd now owns 80,735 shares of the company’s stock valued at $79,000 after purchasing an additional 26,165 shares during the last quarter. EP Wealth Advisors LLC bought a new stake in shares of Hyperfine in the 4th quarter valued at $34,000. Bridgeway Capital Management LLC increased its position in shares of Hyperfine by 50.2% during the fourth quarter. Bridgeway Capital Management LLC now owns 119,700 shares of the company’s stock worth $117,000 after buying an additional 40,000 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Hyperfine during the fourth quarter worth $55,000. 15.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. B. Riley Financial reaffirmed a “buy” rating on shares of Hyperfine in a research note on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperfine in a report on Friday, July 17th. Finally, BTIG Research initiated coverage on Hyperfine in a research note on Wednesday, April 29th. They issued a “buy” rating and a $2.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Hyperfine presently has a consensus rating of “Hold” and a consensus target price of $1.78.

About Hyperfine

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.